Notification Number: 2003/65/F

Order on the rules of good practice relating to the manufacture, packaging, storage, importation, transport and distribution of related therapeutic products.

Date received : 20/02/2003

End of Standstill : 21/05/2003

Issue of comments by : Commission

Message

Message 002

Communication from the Commission - SG(2003) D/50389

Directive 98/34/EC

Translation of the message 001

Notification: 2003/0065/F

Fristerne indledes ikke - Kein Fristbeginn - Καμμία έναρξη προθεσμίας - Does not open the delays - No abre el plazo - N'ouvre pas de délais - Non fa decorrere la mora - Geen termijnbegin - Nao inicia o prazo - Määräaika ei ala tästä - Inleder ingen frist.

(MSG: 200300389.EN)

1. Structured Information Line

MSG 002 IND 2003 0065 F EN 21-05-2003 20-02-2003 F NOTIF 21-05-2003

2. Member State

France

3. Department Responsible

Délégué interministériel aux normes - SQUALPI - 64-70, Allée de Bercy - Télédoc 811 - 75574 PARIS Cédex 12 suzanne.piau@industrie.gouv.fr ou syrte@industrie.gouv.fr

tél: 01 53 44 97 04 - fax: 01 53 44 98 88

3. Originating Department

Ministère de la santé, de la famille et des personnes handicapées.

Direction générale de la santé

Sous-direction de la politique des produits de santé

Bureau des produits de santé d'origine humaine

1, Place de Fontenoy-75700-Paris

Personnes référentes : Madame Hornez tél. : 01-40-56-52-03

Madame Flament tél.: 01-40-56-41-32

4. Notification Number

2003/0065/F - C00P

5. Title

Order on the rules of good practice relating to the manufacture, packaging, storage, importation, transport and distribution of related therapeutic products.

6. Products Concerned

Related therapeutic products: these products are defined in Article L. 1263-1 of the Public Health Code as "any product, with the exception of medical devices [...], which comes into contact with organs, tissues, cells or products derived from the human body or of animal origin during their storage, preparation, processing, packaging or transport before use for therapeutic purposes in human beings, as well as any product which comes into contact with embryos as part of medically assisted procreation."

This legal category of products was created by Act No 98-535 of 1 July 1998 on more stringent health monitoring and health safety checks on health products intended for use on human beings.

At the time of the preparatory work for this Act it was observed that a number of products were being used for therapeutic purposes without undergoing any assessment as regards their quality and efficiency. Following this observation a working group was instructed to compile a list of all the products not subject to a precise legal status and develop proposals for a regulatory framework for these products, according to the potential risks. Those products without status included the related therapeutic products used as a means of preserving grafts or in the preparation of health products of human origin (culture media, etc.).

7. Notification Under Another Act

No.

8. Main Content

The Order lays down the rules of good practice relating to the manufacture, packaging, storage, importation, transport and distribution of related therapeutic products.

These rules stipulate the basic requirements as regards personnel, premises, material, processes and documentation, in order to guarantee the quality of these products.

They consist of four sections dedicated respectively to quality control, preparation of related therapeutic products, the storage, distribution and transport thereof and finally to their importation.

Key words: related therapeutic products, manufacturers, importers, distributors, marketing authorisation, good manufacturing practices.

9. Brief Statement of Grounds

Related therapeutic products of chemical or biological origin are not subject to any safety checks or to any assessment. Some of these products may have undergone an impact assessment and a safety check by the French Agency for the Safety of Health Products when they are used for other purposes (particularly as in-vitro diagnostic medical devices) but these checks do not provide assurance of their safety when used in contact with products of human origin intended for transplanting or with embryos intended for implantation. These related therapeutic products, when used in this way, are currently without status, in French legislation or in European legislation.

BundesMinisterium für Wirtschaft Referat XA2

Frau Christina Jäckel

For this reason, the French health authorities felt it necessary to develop a regulatory framework for all related therapeutic products, largely based on existing checks within the field of medicinal products (marketing authorisation, rules of good manufacturing practices).

authorisation, rules of good manufacturing practices).
10. Reference Documents - Basic Texts Articles of the Public Health Code applying to the implementation of the Decree and Order: Articles L. 1263-1, L.1263-2, L. 1263-3 and L. 1263-4.
11. Invocation of the Emergency Procedure No
12. Grounds for the Emergency
13. Confidentiality No
14. Fiscal measures No
15. Impact assessment No
16. TBT and SPS aspects TBT aspect (Agreement on technical barriers to trade) a) Yes
SPS aspect (Agreement on sanitary and phytosanitary measures)
b) No i) The draft is not a sanitary or phytosanitary measure pursuant to Annex A to the SPS Agreement.
David O'Sullivan Secretary-General European Commission
sent to :

Bundesministerium für Wirtschaft und Arbeit - Abteilung C2/1 Frau MARKL Iris

Bundesministerium für Wirtschaft und Arbeit - Abteilung C2/1 Frau Brigitte WIKGOLM

Departement of Trade and Industry - Stan dards and Technical Regulations - Dir 2 Mrs Brenda O'Grady

Délégation Interministérielle aux Normes Mme Piau

EFTA Surveillance Authority
Mr. Gunnar Thor PETURSSON

ELOT

Mr E. Melagrakis

Erhvervs- og Boligstyrelsen Lene Hald Nielsen

European Free Trade Association

.

Institut Belge de Normalisation Mme F. Hombert

Instituto Portugês da Qualidade Sra. Candida Pires

Kauppa-ja teollisuusministeriö Mr Petri Kuurma

Kommerskollegium Mme Kerstin Carlsson

Min. de Asuntos Exteriores Esther Perez Pelaez

Min. of Industry, Energy & Technology Mr K. Polychronidis

Ministerie van Financien Belastingsdienst - Douane / CDIU De Heer IJ.G. van der Heide

Ministero dell'Industria, del commercio e dell'artigianato Signor P. Cavanna

Ministère des Affaires Economiques Mme Descamps

NSAI



EUROPEAN COMMISSION GROWTH DIRECTORATE-GENERAL

Single Market for goods Prevention of Technical Barriers

Mr Tony Losty
National Agency for Enterprise & Housing Laila Østergren
Représentation Permanente de la Belgique auprès de l'Union européenne .
Représentation Permanente de la France
Représentation Permanente du Luxembourg
SL
SPERATI Marie
Service de l'Energie de l'Etat Mr JP. Hoffmann
sent to :
Departement of Trade and Industry - Stan dards and Technical Regulations - Dir 2 Mrs Brenda O'Grady
EC .
EFTA Surveillance Authority Mr. Gunnar Thor PETURSSON
ELOT Mr E. Melagrakis
European Free Trade Association .
Kauppa-ja teollisuusministeriö Mr Petri Kuurma
Kommerskollegium Mme Kerstin Carlsson
Min. of Industry, Energy & Technology Mr K. Polychronidis



EUROPEAN COMMISSION GROWTH DIRECTORATE-GENERAL

Single Market for goodsPrevention of Technical Barriers

Ministerie van Financien Belastingsdienst - Douane / CDIU De Heer IJ.G. van der Heide

NSAI Mr Tony Losty

Représentation Permanente de l'Irlande Denis Colfer

Représentation Permanente du Royaume-Uni

.

Undersecretariat of Foreign Trade General Directorate of Standardisation Saadettin DOGAN